Lenvatinib mesylate is a potent multi-receptor tyrosine kinase inhibitor used in the clinical treatment of differentiated thyroid cancer that has progressed despite radioactive iodine therapy, as well… Read more
Lenvatinib mesylate is a potent multi-receptor tyrosine kinase inhibitor used in the clinical treatment of differentiated thyroid cancer that has progressed despite radioactive iodine therapy, as well as renal cell carcinoma and hepatocellular carcinoma. By targeting receptors involved in tumor growth and angiogenesis, this therapeutic agent requires rigorous quality control and analytical validation throughout its development and manufacturing lifecycle. This category provides access to high-quality reference standards for the lenvatinib mesylate active pharmaceutical ingredient, alongside a comprehensive selection of its related impurities, degradants, and metabolites. Laboratories rely on these materials for accurate impurity profiling and method validation during stability testing. Additionally, stable isotope labelled compounds are available to serve as internal standards for precise quantification in mass spectrometry-based bioanalytical assays, ensuring compliance with strict regulatory requirements in the pharmaceutical industry.